Join Valneva for a hybrid investor day in New York City, featuring speakers from company management, who will discuss the company’s key near- and mid-term growth drivers:

• Valneva’s robust R&D pipeline of potentially first-, only-, or best-in-class vaccine candidates addressing major unmet medical needs in infectious disease: Lyme disease (Phase 3, led by Pfizer), Shigella (Phase 2), and Zika (Phase 1)
• Valneva’s growing portfolio of revenue-generating vaccines, including the launch of world’s first and only approved vaccine against chikungunya virus

A live question and answer session will follow the formal presentation.